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Abstract 
 
Antibiotic-resistant bacteria and chronic wound infections pose a serious threat to 
patient health and overall quality of life. The goal of this project was to determine the action 
mechanism of fCBD-LL37 against phosphatidylcholine lipid bilayer using a quartz crystal 
microbalance with dissipation. At increased concentrations, fCBD interacted to a greater 
extent with the lipid bilayer indicating that the tethered fCBD-LL37 shows greater peptide 
bondage to bilayer. This is the foundation of the development of bipolymer-tethered AMPs 
for wound healing applications. 
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Chapter 1: Introduction 
Chronic wound infections pose a serious threat to patient health and overall quality 
of life, and billions of dollars are spent in the United States each year for chronic wound 
treatments. Current approaches to mitigate them such as antibiotics and silver are becoming 
increasingly ineffective because of bacterial resistance and inhibition of healing. Thus, 
there is a pressing need for alternative approaches that treat wound infections and also 
facilitate functional tissue repair (Center of Disease Control, 2016). 
Antimicrobial peptides (AMPs) are a promising alternative treatment because of 
their broad-spectrum antimicrobial activities. AMPs are short, naturally-occurring peptides 
that display a generally physical mechanisms of membrane disruption (Wang, 2016). This 
allows for antimicrobial activity against antibiotic-resistant organisms and a low chance 
for the development of resistance. Many AMPs, such as the human LL37 have additional 
immunomodulatory activities that are attractive as wound treatments (Lozeau, Grosha, 
Kole, Prifti, Dominko, Camesano, Rolle, 2016). There are over 2,600 natural AMPs that 
could be utilized as a diverse platform for the development of new antimicrobial agents, as 
well as, target antibiotic-resistant agents (Center of Disease Control, 2016). However, due 
to their cytotoxicity at high concentrations, more research must be done prior to their 
clinical use to improve their therapeutic index for preventing infection wound healing 
applications. 
Targeted delivery of AMPs bound to collagen scaffolds may broaden AMP 
technologies for clinical wound healing application (Lozeau et al, 2016). Collagen is a 
prevalent biopolymer in repairing tissues and commercially available wound dressings 
(Lozeau, Grosha, Kole, Prifti, Dominko, Camesano, Rolle, 2016). Although several prior 
studies have explored tethering of AMPs, the tethering of AMPs with biopolymers such as 
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collagen remain unknown (Lozeau, Grosha, Kole, Prifti, Dominko, Camesano, Rolle, 
2016). Previously, two modified versions of the human LL37 were designed with collagen-
binding domains (CBDs) and studied for their collagen-binding and bioactivity (Lozeau et 
al, 2016); however, it is unknown whether adding CBD alters LL37’s mechanism of 
interaction with membranes.  
The overall goal of this project is to determine the action mechanism of one of these 
CBD peptides, fCBD-LL37 with a CBD derived from fibronectin, against zwitterionic 
phosphatidylcholine (PC) lipid bilayers. We chose to study fCBD-LL37 because from prior 
research, it is found that fCBD is less cytotoxic and preserves its antimicrobial activity. To 
do this, we used the quartz-crystal microbalance with dissipation (QCM-D) to develop a 
better understanding for the molecular basis of fCBD-LL37 mechanisms as a function of 
concentration (Wang, 2015). The obtained frequency (Δf) and (ΔD) values were analyzed 
in terms of time, overall changes, and molecular fingerprint at the different peptide-to-lipid 
ratios (P/L). From this, we were able to develop a hypothesis for the action mechanism of 
fCBD-LL37 as a function of concentration. These studies will allow us to observe how 
adding fCBD affected LL37 bioactivity, provide a foundation for future research, and aid 
in the development of biopolymer-tethered AMPs for wound healing applications. 
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Chapter 2: Literature Review 
 
I.  The Antimicrobial Resistance Crisis 
The number of infections caused by multidrug-resistant bacteria is increasing due 
to high use and reliance on antibiotics (Center of Disease Control, 2014). It is estimated 
that in the United States, 2 million people are infected with antibiotic-resistant bacteria 
annually that results in approximately 23,000 deaths (Blair, Webber, Baylay, Ogbolu, 
Piddock, 2015).  
Resistance can occur by many routes, and new resistance mechanisms are 
constantly being described (Blair, Webber, Baylay, Ogbolu, Piddock, 2015). Mechanisms 
such as antibiotic control programs, better hygiene, and synthesis of agents with improved 
antimicrobial activity need to be adopted in order to limit bacterial resistance (Neu H, 
1992). Unfortunately, the approval of alternative antimicrobial agents has been dwindling. 
This is particularly a problem in situations where alternatives such as silver or chemicals 
should not be used, such as in chronic wounds.  
 
II.  Chronic Wounds 
Wound healing is an essential process for the repair and restoration of function 
tissue after injury. After a wound is infected, healing begins with inflammation, is followed 
by a period of tissue regeneration including epithelialization, angiogenesis and ends with 
remodeling to restore the tissue (Mangoni, McDermott, Zasloff, 2015). A wound that does 
not heal in an orderly set of stages and in a predictable amount of time can lead to the 
formation of non-healing chronic wounds (Mangoni, McDermott, Zasloff, 2015). Chronic 
wounds (such as ulcers, burns and surgical site infections) represent a significant burden 
to patients and healthcare professionals, affecting approximately 5.7 million patients and 
costing approximately $20 billion annually (Torre, 2015). Typically, antimicrobial agents 
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are used during wound treatment to mitigate the chance of infection in addition to the use 
of wound scaffolds that help the functional tissue repair.  
 
The Use of Scaffolds for Chronic Wound Treatment 
Recent advances in our understanding of chronic wound biology have led to the 
development of several new treatments that offer renewed hope to patients with ulcers and 
other chronic wounds. Factors underlying the wound healing problems experienced in 
individual patients should allow better tailored treatment to each individual. Allogeneic 
skin grafting (transplanted between people who are not genetically identical) and 
bioengineered skin equivalents are being used successfully in patients with venous leg 
ulcers and diabetic patients with foot ulcers (Morris, Patel, 2002). Bioengineered skin 
consists of an outer epidermal layer and/or a dermal layer (the layer of skin between the 
epidermis and the subcutaneous tissue) embedded into an acellular matrix (a support 
structure) forming a biological skin substitute (Ranaweera, 2011). Bioengineered skin graft 
Alloderm is currently being used for burn and full thickness wounds (Ranaweera, 2011). 
Skin tissue donated from cadavers are used to make an acellular dermal matrix that has 
been freeze-dried after processing. It is used to serve as a scaffold for normal tissue 
remodeling (Ranaweera, 2011). The collagen framework provides strength to the skin and 
contains no cells that can cause rejection or irritation (Ranaweera, 2011). 
Despite the growing number of new wound dressings and therapeutics, current 
scientific data is incomplete, and evidence for the effectiveness of these wound dressings 
combined with antimicrobial treatment is sparse. A combination approach of wound-care 
management (debridement and scaffolding), systemic antibiotics, and a topical 
antimicrobial agent has been shown to reduce the ability of the infection to persist (Wolcott 
and Rhoads, 2008; Lopez-Leban et al., 2010; Wolcott et al., 2010) and has been shown to 
be one effective approach to healing these wounds. Unfortunately, these multifaceted 
treatments can also be costly. Alternatively, silver dressings are used to prevent infection, 
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but it is scrutinized for its inability to promote healing (Castellano, Shafii, Ko, Donate, 
Wright, Mannari, Payne, Smith, 2007). No significant advantage of one wound dressing 
over the other currently exists which increases the chance of wounds being more likely to 
be infected (Vasa, 2013). 
 
Chronic Wound Infection 
Chronic wounds are highly susceptible to infection, which severely complicates 
treatment, these wounds are also expensive to treat costing about $25 billion annually on 
treat (Sen, Gordillo, Roy, Kirsner, Lambert, Hunt, Gottrup, Gurtner, Longaker, 2009). 
When there is infection, various bacteria may form biofilms on the wound surface, which 
are characterized by an aggregation of bacterial cells immobilized in an impenetrable 
adhesive matrix made of extracellular polymeric substances. Biofilms make the eradication 
of bacteria difficult, mainly due to the weak penetration of antibiotics or host clearance 
mechanisms (Mangoni, McDermott, Zasloff, 2015). Wound infections are currently treated 
with antibiotics, such as aminoglycosides (see Appendix A for list of common antibiotics). 
Using antibiotics unnecessarily or incorrectly increases the risk of bacteria developing 
resistance to antibiotics. Furthermore, many wounds are polymicrobial (consisting of many 
bacterial species), which are difficult for antibiotics to target. There is a need for new ways 
to avoid bacterial resistance, combat polymicrobial infection, and help heal chronic 
wounds. 
 
III.  Antimicrobial Peptides are a Promising Alternative 
Antimicrobial peptides (AMPs) have shown promise in helping with the antibiotic 
resistance crisis and the treatment of chronic wounds. AMPs are small molecular weight 
proteins with the broad-spectrum antimicrobial activity against bacteria, viruses and fungi. 
They are usually positively-charged (net charge between −3 and +20) (Wang, G 2014). 
They also are amphipathic, and have both hydrophobic and hydrophilic residues that enable 
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the molecule to be soluble in both aqueous environments and lipid-rich membranes (Wang, 
G 2014). The unique physical interaction mechanisms of AMPs with lipid membranes lead 
to a lower likelihood to bacterial resistance, making AMPs highly promising for the clinic. 
However, despite significant progress in the past 30 years, no peptide antibiotic has reached 
the clinic yet. Poor understanding of the action mechanisms and lack of rational design 
principles have been the two major obstacles that have slowed progress (Li, Koh, Liu, 
Lakshminarayanan, Verma, Beuerman, 2017).  AMPs also have a high production cost 
estimated at $300-$500 per gram (Bray 2003; Vlieghe et al. 2010). These shortcomings 
could be improved with a better understanding of the exact mechanisms of AMP 
interactions, because then, alternative and less toxic designs of AMPs could be designed. 
 
IV. Human Cathelicidin AMP LL37  
 
Cathelicidins are a family of mammalian AMPs found in the granules of neutrophils 
and are synthesized as preproproteins. After removal of a signal peptide, they are stored in 
granules as inactive proforms. The active biologic domains of the cathelicidins reside in 
the C-terminus, with the N-terminus having a conserved cathelin-like domain. Commonly 
studied examples of cathelicidins including ovine SMAP-29, bovine indolicidin, and 
porcine PR-39 (Wang K, 2015). 
 
The only human-derived cathelicidin is LL37, a 37-aa protein (see LL37 sequence 
in Figure 1). LL37 demonstrates broad antimicrobial, anti-biofilm and immunomodulatory 
activities. Fifty-four percent of LL37’s residues are hydrophilic with 11 basic and 5 acidic, 
giving it a net positive charge of +6 at physiological pH. In aqueous solution, LL37 has a 
disordered structure, but when exposed to a lipophilic environment, many of the amino 
acids are able to form intramolecular hydrogen bonds locking the secondary structure into 
an α-helix (Duplantier, van Hoek, 2013). When administered topically, can potentially 
avoid the many hurdles of systemic peptide delivery (Duplantier, van Hoek, 2013). An 
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intriguing aspect of LL-37 with respect to skin wounds is its interaction with keratinocytes. 
Keratinocytes, the predominant cell type found in the epidermis, form barriers against 
microbial pathogens during wound closure, and keratinocyte migration is an important step 
in skin wound healing (Duplantier, van Hoek, 2013). hCAP-18 is strongly expressed in 
healing skin epithelium, and treatment with antibodies raised and affinity purified against 
LL-37 inhibited re-epithelialization (wound closure) in a concentration-dependent manner 
(Heilborn et al., 2003). However, action mechanisms of LL37 are not fully understood to 
start using clinical applications. The combination of the anti-biofilm and pro-wound 
healing properties of LL37 may make it highly effective in resolving polymicrobial-
infected wounds, which could make it an excellent alternative therapeutic for chronic 
wounds.   
 
LL37 Modified to Bind to Collagen-Based Materials 
 
In order to mitigate cytotoxicity and maintain activity while delivering LL37 to a 
wound site, research was done to investigate the effects of tethering human AMP 
cathelicidin LL37 to collagen. Collagen is one of the main extracellular matrix proteins in 
wound sites, and in commercially-available wound dressings. The active domain of LL37 
was modified by fusion to two different collagen binding domains (CBD) (see Figure 1 
for CBDs), one from derived from collagenase (cCBD-LL37) and one derived from 
fibronectin (fCBD-LL37) (Lozeau, Grosha, Kole, Prifti, Dominko, Camesano, Rolle, 
2016). This study found that fCBD-LL37 is less cytotoxic in solution than cCBD-LL37 
and LL37 and the biopolymer-tethered AMPs may represent a viable alternative for 
preventing and treating wound infection while also supporting tissue repair. 
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Given the unique, non-toxic action of fCBD-LL37 from this recent study in 
particular, we were interested in the interaction mechanisms of fCBD-LL37 with 
zwitterionic mammalian cell membranes and the role that fCBD plays in that mechanism. 
There are many possible mechanisms that AMPs could adopt when faced with zwitterionic 
lipid membranes. 
 
 
V.  Proposed AMP-Lipid Interaction Mechanisms 
 
 The overall mechanism of AMPs is determined their ability to cause damage to cell 
membranes. The composition of the cell membrane plays a role in determining the potency 
and specificity of AMPs. The sensitivity of the bacterial and mammalian cells to AMPs is 
directly mediated by the physicochemical properties of the lipids found in each type of 
membrane (Dathe and Wieprecht, 1999). Indeed, the negative charge of bacterial 
Figure 1:Full structure of cCBD-LL37 and fCBD-LL37 precursors taken from (Prifti, 2012). The AMP includes three FLAG domains 
and the cathelin-like signal and pro-sequences, all of which are cleaved after cellular secretion, leaving the LL37 active domain 
(magenta), one FLAG sequence as a spacer and identifiable sequence (yellow) and the collagen binding domain (orange). 
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membranes (anionic lipids for example phosphatidylglycerol and cardiolipin) is important 
for preferential binding of some AMPs, including LL37, to microorganisms. This 
interaction is governed by electrostatic interactions between cationic AMPs and anionic 
bacterial membranes.  
 
 When encountering zwitterionic lipids (such as phosphatidylcholine), then there are 
relatively weaker attractive interactions between neutral membranes and AMPs (Wang, 
2014). In this case, hydrophobicity may be more significant in determining activity. 
Hydrophobicity has been shown to affect the antimicrobial and hemolytic activity of AMPs 
(Wang, 2014). Numerous studies have examined the relationship between many AMPs’ 
structures and their resulting bioactivities. However, in the case of LL37, its structure, 
physicochemical properties and mechanisms of cytotoxicity are still controversial. It is 
generally agreed upon that for LL37, its mechanism depends on several properties such as 
peptide-to-lipid ratio (P/L), charge, sequence and secondary structure orientation and 
aggregation (Guilhelmelli, et al., 2013). Several models relating these properties have been 
proposed (Figure 2). 
16 
 
  
 
The proposed models for AMP mechanisms include the toroidal pore, barrel-stave, 
non-pore carpet, and detergent-like carpet models (see Figure 2). The exact mechanism 
that LL37 adopts against zwitterionic membranes is still not clearly understood. In fact, 
many different mechanisms have been proposed, including the toroidal pore, non-pore 
carpet, and detergent-like carpet mechanisms. It is possible that fCBD-LL37 follows 
similar or vastly different mechanisms than LL37, mediated by its unique CBD. 
Figure 2:Commonly cited models for antimicrobial peptide activity. Figure 2a represents the adsorption of AMP on the membrane surface, 
Figure 2b represents the Barrel-stave Pore mechanism, Figure 2c represents Torodial Pore mechanism, Figure 2d represents the Carpet 
Model and Figure 2e represents the Detergent Model. Barrel-stave and toroidal pores are membrane-spanning aqueous channels. 
Antimicrobial peptides are described with the carpet model. Such peptides permeabilize membranes by “carpeting” the bilayer. Picture 
adapted from Academic paper: Plant Antimicrobial Peptides. Available from: 
https://www.researchgate.net/publication/302072901_Plant_Antimicrobial_Peptides [accessed Mar 31, 2017] 
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In the toroidal model, AMPs are inserted into the membrane forming a bundle, 
inducing the lipid monolayers to continuously bend through the pore (Yang et al., 2001) 
(Figure 2c). This is often dependent on AMP aggregation. As a result, the membrane lipids 
become interspersed with AMPs (Yeaman & Yount, 2003). An important aspect of this 
mechanism involves an induction of positive curvature strain in the bilayer by the AMP at 
high concentrations, leading to the formation of small and transient lipid-AMP pores 
(Wildman, Lee,  & Ramamoorthy, 2002). LL37 was shown to do this, using NMR 
spectroscopy, in PE lipid bilayers that typically favor negative curvature (Wildman, Lee, 
Ramamoorthy, 2002). Other examples of AMPs that form toroidal pores are magainins, 
protegrins, and melittin (Brogden, 2005). 
 
In a barrel stave pore (Figure 2b), peptides interact laterally with one another to 
form a specific structure that is reminiscent of a membrane protein ion channel.  Barrel 
stave pores work with the bilayer hydrocarbon core, using it as a template for peptide-self 
assembly (Wimley, 2011). Additional monomers can increase the pore size, allowing 
cytoplasmic content leaking with subsequent cell death. In this mechanism, peptide 
secondary structures, such as hydrophobic α-helix and/or β-sheet, are essential to pore 
formation (Breukink and de Kruijff, 1999). These peptide regions interact with the 
membrane lipids, while the hydrophilic peptide regions form the lumen of the channel 
(Brogden, 2005). 
 
In the non-pore carpet model (Figure 2c), AMPs align themselves parallel to 
membrane surface, facilitated by their amphipathicity. The AMPs must first bind onto the 
surface of the target membrane, possibly in monomeric form, and cover it in a “carpet”-
like manner (Oren Z., Shai Y, 2001). Initial interaction is driven by electrostatics in the 
case of anionic lipids, and amphipathicity in the case of zwitterionic lipids. When the 
amount of AMPs on the membrane surface reaches a critical threshold concentration, the 
18 
 
membrane is permeated, wholly disrupted, and is disintegrated at the highest AMP 
concentrations (Oren and Shai, 1998). The threshold concentration (denoted as P/L*) 
depends upon the composition of lipid membrane. Well-defined pores do not occur in this 
model. A study was done to investigate the the active conformation in the membranes of 
LL37 by reconstituting LL37 into nto dodecylphosphocholine (DPC) micelles and 
determine its 3D structure (Porcelli et al., 2008). It was found that under experimental 
conditions the peptide adopts a helix-break-helix conformation (Porcelli et al., 2008). 
When it interacts with DPC, LL-37 is adsorbed on the surface of the micelle with the 
hydrophilic face exposed to the water phase and the hydrophobic face buried in the micelle 
hydrocarbon region. These results support the proposed nonpore carpet-like mechanism of 
action, in agreement with the solid-state NMR studies (Porcelli et al., 2008). 
 
In detergent-like carpet model (Figure. 2e), AMPs surround the lipids and carpet 
on the surface as they do in the non-pore carpet mechanism. However, at P/L*, peptide-
lipid micelles break off from the lipid membrane, causing large defects in the membrane, 
lysis and cell death. A detergent-like mechanism, was rated unlikely to be the mechanism 
of LL37 because of the rapidly tumbling membrane fragments that were not observed in 
NMR experiments carried out (Sevcsik et al., 2007). This dual behavior of LL-37 can be 
attributed to a balance between electrostatic interactions reflected in different penetration 
depths of the peptide and hydrocarbon chain length. This study indicates that there is a tight 
coupling between the peptide properties and those of the lipid bilayer, which needs to be 
considered in studies of lipid/peptide interaction (Sevcsik et al., 2007). In extension to 
these studies observations on PG and PC model membranes clearly demonstrate that the 
peptide LL-37 does not act by one single molecular mechanism, but causes membrane 
disruption by distinctly different mechanisms strongly dependent not only on the nature of 
the lipid headgroup but also on the hydrocarbon chain length (Sevcsik et al., 2007). 
 
However, it has been described that AMPs might also form transmembrane pores 
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at concentrations below the threshold, suggesting that the mechanism by which the peptide 
disrupts the membrane depends on its concentration (Lohner, 2009). It is possible that 
derivatives of LL37 such as fCBD-LL37 have similar mechanisms; however, the low 
toxicity of fCBD-LL37 compared with LL37 alone suggests that these mechanisms may 
deviate particularly in the case of zwitterionic membranes. Further, the structure of fCBD-
LL37 may cause alternate conformations on the lipid surface leading to different outcomes 
for interaction mechanisms. It was suggested previously that fCBD-LL37 may aggregate, 
thus helping to lower its toxicity. 
 
VI.  QCM-D: A Method to Elucidate fCBD-LL37 Mechanism 
Quartz crystal microbalance with dissipation (QCM-D) is a versatile technique for 
investigating AMPs. QCM-D measures a mass variation per unit area by measuring the 
change in frequency (Δf) of a piezoelectric quartz crystal resonator. The added advantage 
of measuring dissipation (ΔD) changes allows additional film properties to be investigated 
(Dixon M, 2008). ΔD is related to the rigidity of the film. The QCM-D measures these 
responses for various overtones, or multiples of the resonant frequency (5 MHz). Overtones 
can be correlated with the changes in depths of a film deposited on the crystal (Dixon M, 
2008). The QCM-D is a non-destructive flow system, which allows all of these changes to 
be measured in real-time, giving more information about interaction mechanisms than 
spectroscopic systems, which are both destructive and limited to one point in time during 
the interaction. The use of QCM-D for experiments is promising for the differentiation of 
peptide mechanisms. 
QCM-D can give information about mass deposition, changes in bilayer integrity 
the dynamics of AMP–membrane interactions (Dixon, 2008). Previously, AMP 
mechanisms were investigated versus zwitterionic phosphatidylcholine (PC) lipid bilayers 
(Wang, 2015). A bilayer was formed in the QCM-D, and varying concentrations of AMP 
were injected through the system. From the changes in ΔD and Δf, mechanisms were 
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proposed. For example, Indolicidin, a 13-residue bovine cathelicidin that assumes a unique 
folded conformation when in contact with PC (Wang, 2015), was found to create 
substantial changes in the PC membranes at concentrations above 1 μM in the QCM-D 
experiments that correlated with the Minimum Inhibitory Concentration (MIC) of 1 to 13 
μM for various bacteria and hemolytic concentrations (Wang, 2015). Even more 
information about AMP mechanisms were found by further analysis of the raw data in 
polar plot form (ΔD vs. Δf). Using polar plots, the unique fingerprint for indolicidin’s 
mechanism was compared to three other AMPs, and allowed differentiation of the 
phenomena directly occurring at bilayer during AMP-PC interaction. This gave more 
insight to the interaction than simple ΔD and Δf changes alone.  
Our goal to determine the action mechanism of chimeric fCBD-LL37 against PC 
bilayers using QCM-D as a function of peptide concentration to develop a better 
understanding for the molecular basis of fCBD-LL37 mechanisms. We investigated the 
initial and overall interactions of fCBD-LL37 with PC over time at different concentrations. 
Polar plots were constructed to create a unique fingerprint for fCBD-LL37 and to extract 
information about the dynamics of its interactions with PC, and were compared to previous 
studies. Lastly, we were able to propose a unique mechanism for fCBD-LL37 and describe 
the role that adding fCBD has in determining mechanistic variations, and ultimately, 
determining the possible cytotoxic actions of fCBD-LL37. The results found in this project 
will further help the understanding of AMPs for future development in areas such as wound 
healing and replacing antibiotics. 
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Chapter 3: Materials and Methods 
 
I. Materials 
 
Synthetic LL37 (LLGDFFRKSKEKIGKEFKRIVQRIKDFLRRTES) was 
purchased from Anaspec, Inc. (Fremont, CA) at >95% purity. It was confirmed by high-
performance liquid chromatography (HPLC).  
The modified LL37 peptide with a fibronectin-derived CBD (fCBD-LL37) 
(LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTESDYKDDDDKCQDSERTFY) 
was synthesized by New England Peptide, Inc. (Gardner, MA) at >90% purity. This peptide 
was also confirmed by HPLC. A FLAG™ domain (DYKDDDDK) linker sequence was 
included between the LL37 and CBD sequences in each peptide to preserve flexibility, and 
as an epitope tag. The peptides were received at greater than 90% purity confirmed by high 
performance liquid chromatography. Stock solutions (0.67 mM) of each AMP were 
prepared according to manufacturer recommendations (LL37 in sterile PBS (pH 7.2) and 
cCBD- and fCBD-LL37 in sterile water (pH 3.5), each supplemented with 5 mM 
ethylenediaminetetraacetic acid (EDTA)) and stored at -20°C. Deionized water was taken 
from a MilliporeSigma Milli-Q Integral water purifier. Sodium chloride and 
tris(hydroxymethyl)aminomethane were purchased from Sigma-Aldrich. Peptide and lipid 
vesicle solutions were prepared in Tris–NaCl buffer (100 mM sodium chloride and 10 mM 
tris(hydroxymethyl)aminomethane at pH 7.8). Sodium hydroxide and hydrochloric acid 
were diluted from a stock solution to regulate the pH of the buffer. The QCM-D instrument 
used was purchased from Biolin Scientific along with QCM-D crystals that are coated in 
silicon dioxide (SiO2) 
 
II. Methodology 
 
3.1     Tris-NaCl Buffer 
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A Tris-NaCL Buffer solution and SDS buffer solution were prepared by first 
measuring out 1.168g NaCl and 0.24 g Tris into a clean 250 mL beaker. Then, 200 mL of 
deionized (DI) water was added to the beaker. The beaker was then placed on a stir plate 
and the solution was stirred for approximately 5 minutes or until the mixture was dissolved. 
The pH meter was calibrated using the pH 7 and 10 solutions. After the NaCl and Tris 
dissolved, the pH of the solution was measured using the pH meter. The initial pH of the 
solution is usually around 8.5. The pH of the buffer solution was adjusted to pH 7.8 using 
HCl or NaOH to make the solution more acidic or basic.  
 
3.2    Dilute Egg PC Solution 
 The initial concentration of egg PC solution is 2.5 mg/mL. The concentration of 
egg PC had to be diluted to 0.1 mg/mL in order to be ran through the quartz crystal 
microbalance with dissipation (QCM-D). To make a dilute lipid solution, the stock solution 
of lipids at 2.5 mg/mL PC egg solution were first vortexed. The test tube was cleaned with 
ethanol and a kimwipe. The concentrated lipid solution was diluted by first adding 0.24 
mL of concentrated egg PC solution into a test tube containing 5.76 mL of Tris-NaCl buffer 
solution. Vortex the solution briefly prior to flowing through the QCM-D. 
 
3.3     Freeze/Thaw Methodology 
 First, dry ice was obtained in a styrofoam container and broken into pieces for the 
test tube to be completely surrounded by ice. Then, the test tube containing 
the  concentrated egg PC solution was placed at a slant in the container of dry ice between 
the crevices of the dry ice. The test tube was left in the container for about 15-20 minutes 
to allow the PC solution to freeze. After freezing, the test tube was placed into a water bath 
and the solids were monitored until a phase change from solid to liquid occured. The 
procedure was repeated for a total of 5 cycles. The freezing should take approximately 13-
15 minutes, the thawing should take approximately 5-7 minutes and the vortexing should 
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be about 15 seconds for cycles 2-5. After following the above steps continue to sonication.  
 
3.4      Sonication/Centrifugation  
 A 250 mL beaker was packed tightly with normal ice leaving very little extra space 
and the top of the cylinder was covered with foil. After completing the freeze/thaw cycles 
(part 3), the contents of the polyethylene tube were transferred into the open and parafilmed 
glass or plastic tube. The test tube was placed into the beaker filled with ice and taped to 
the aluminum foil to ensure that the test tube will not move. Finally, the test tube was 
sonicated for 30 minutes under the conditions listed in the table below. 
Table 2: Sonicate test tube under these conditions 
Sonication condition settings 
Mode: Pulse mode 
Amplitude setting: 60% Duty cycle 
Frequency: 30 Hz 
Time: 30 minutes 
3 seconds on, 7 seconds off 
After sonication the solution was then put in a centrifuge. Two new polyethylene test tubes 
were cleaned to place the liquid into a fresh test tube and add water to the other. More water 
was added to the test tube containing water to account for the weight because of the 
difference in density of the two (2) solutions. Both test tubes were placed in the centrifuge 
across from one another in order to balance the centrifuge. The centrifuge was operated at 
15,000 RPM for 10 minutes. After 10 minutes both test tubes were removed. A 
micropipette was used to remove supementant (liquid) so as to not disturb the pellets and 
place into the other cleaned polyethylene test tube. The solution was dried with nitrogen or 
approximately 20 seconds and store the solution in the refrigerator at 4℃ for up to one (1) 
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month.  
 
3.5        QCM-D Bilayer Formation Procedure 
 Silica-coated sensor crystals were placed into the QCM-D flow chambers and 
cleaned by flowing ethanol, deionized water and 2% sodium dodecyl sulfate (SDS) solution 
through all four (4) chambers at 0.35 mL/min. After cleaning, the sensors and chambers 
were dried with nitrogen gas. A Plasma Prep II, oxygen plasma cleaner, was used to etch 
the crystal’s sensor surface before each experiment to remove the outer atomic layers of 
the crystal surface and make it more hydrophilic. Buffer was flowed over QCM-D sensors 
at 0.15 mL/min for approximately 15 min at 23℃ or until the frequency and dissipation 
response were stable. The lipid solution was flowed over the crystals for approximately 8 
minutes to form a stable supported lipid bilayer (SLB). The crystals were rinsed with buffer 
to remove any unattached lipids. After establishing a baseline, peptide solution was added 
for 10 min, at which time the pump was stopped. QCM-D crystals were exposed to a 
stagnant peptide solution for 1 h, after which the peptide solution was replaced with a final 
buffer rinse at 0.15 mL/min until the frequency stabilized. After running the QCM-D to 
facilitate the vesicle rupture into a bilayer the sensor crystals were cleaned again by flowing 
ethanol, deionized water and 2% sodium dodecyl sulfate (SDS) solution through all four 
(4) chambers at 0.35 mL/min. 
 
 The bilayer formation was monitored by observing patterns in the QCM-D 
frequency and dissipation. After bilayer formation, the A complete bilayer could be 
characterized by a final Δf of -26 Hz and change in dissipation (ΔD) of ∼1x106 in the third 
harmonic. Then tris-NaCl buffer was flowed for 10 minutes, followed by the introduction 
of the fCBD peptide being flowed for 10 minutes. After peptide flow, the peptide was left 
to incubate for an hour. Followed by incubation there was a final flow or tris-NaCl buffer 
for 10 minutes. These procedures were repeated for all eight (8) concentrations.  
25 
 
 
3.7         Part 6: Data Analysis 
 
As the experiment was being run by the QCM-D, the raw data was recorded in the 
QSoft software where we were able to monitor in real-time, the activity above the surface 
of the crystal. After completing the experiment, the data was then exported from QSoft to 
a different software called QTools, which allows us export the data onto an excel 
spreadsheet. The raw data was then organized on the excel spreadsheet and inputted into 
Sigmaplot. Sigmaplot was the software we used to create our real-time trace responses and 
bar graphs. We also ran statistical analyses (Anova, Tukey, and SNK) through this 
software. 
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Chapter 4: Results and Dicussions 
At 0.01-0.25 µM concentration fCBD-LL37 does not interact 
significantly  
Figure 3: Figure 3a shows frequency (Δf) and dissipation (ΔD) vs time line plot graphed in SgimaPlot. 
This graph shows a replicated experiment using a QCM-D of 0.01 concentration fCBD-LL37. Figure 3b 
shows frequency (Δf) and dissipation (ΔD) vs time line plot graphed in SgimaPlot. This graph shows a 
replicated experiment using a QCM-D of 0.05 concentration fCBD-LL37. This graph shows one 
interaction pattern of two observed at 0.05 concentration.  Figure 3c shows frequency (Δf) and 
dissipation (ΔD) vs time line plot graphed in SgimaPlot. This graph shows a replicated experiment using 
a QCM-D of 0.1 concentration fCBD-LL37. In this graph range of dispersion in the dissipation lines can 
be observed from ~0.0x106 to ~0.2x106. Figure 3d: Frequency (Δf) and dissipation (ΔD) vs time line plot 
graphed in SgimaPlot. This graph shows a replicated experiment using a QCM-D of 0.25 concentration 
fCBD-LL37. This graph shows the second interaction patterns observed at 0.25 concentration fCBD. 
  
Figure 3a: Figure 3b: 
Figure 3c: Figure 3d: 
27 
 
The lowest concentration studied, 0.01 µM, during bilayer formation, Δf decreased 
to approximately -70 Hz when the vesicles adsorbed and showed an increase when the 
vesicles ruptured to form the bilayer (Figure 3a). The ΔD showed an increase to ∼6x106 
in response to the attachment of the water-filled vesicles. A complete bilayer could be 
characterized by a final Δf of around -26 Hz and change in dissipation ΔD of approximately 
zero (0). The Δf value remained constant throughout the experiment at approximately -26 
Hz. After bilayer formation, ΔD increased to approximately 0.5x106. The tris-NaCl buffer 
was introduced at the about 10 minutes and there was decreased in dissipation to 0.2x106. 
Immediately after the decrease to 0.2x106 the ΔD increased to 0.5x106. The dissipation 
decreased at a steady rate to approximately zero (0) after peptide the peptide is introduced 
at 20 minutes and continues to remain at constant rate during peptide incubation and after 
the final buffer rinse at the last 10 minutes shown on the graph. 
 
At 0.05 µM concentration fCBD-LL37 two different peptide 
interactions were observed 
 
In Figure 3b after bilayer formation, tris-NaCl buffer was flowed at about 10 
minutes and Δf decreased to about -27 Hz. The frequency decreased at a steady rate to 
approximately -28 Hz after peptide was introduced at 20 minutes and continued to remain 
at a constant rate during peptide incubation and after the final buffer rinse at the last 10 
minutes shown on the graph (Figure 3b). After the bilayer formation, ΔD increased 
drastically from ~0.2x106 to ~1.8x106. After this drastic increase, dissipation started to 
gradually decrease after 10 minutes to ~0.1x106. After 20 minutes, there was a small 
increase in ΔD to ~0.5x106 which then decreases to ~0.2x106. The ΔD value then increased 
to 1.0x106 and stayed at a constant rate this the end of the experiment.  
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At 0.1 µM concentration fCBD-LL37 line graphs start to show 
more dispersion in the dissipation interaction patterns 
 
Unlike 0.05 µM concentration fCBD, 0.1 fCBD µM showed one (1) interaction 
pattern (see Figure 3c). The concentration 0.1 µM fCBD, displayed reproducible 
interaction patterns throughout the various replicates. In Figure 3c, the graph shows similar 
interaction patterns to the graph in Figure 3b. After the introduction of peptide, Δf values 
decreased slightly from -26 Hz to -28 Hz. After 20 minutes, during peptide incubation Δf 
remained constant at -26 Hz till the end of the experiment. After tris-NaCl buffer was run 
at 10 minutes, ΔD increased from ~0.1x106 to ~1.0x106 followed by another decrease from 
~1.0x106 to ~0.1x106. After the peptide was introduced, ΔD had a second (2) increase from 
~0.1x106 to ~0.8x106. During peptide incubation, there was dispersion throughout the 
different overtones of ΔD until the final buffer run, where frequency values made a slight 
decline and dissipation values made an incline.  
 
At 0.25 µM concentration fCBD-LL37 two different peptide 
interactions are shown 
 
 In Figure 3d, after bilayer formation, the buffer was flowed at about 10 minutes 
and Δf decreased to about -27 Hz. The frequency decreased at a constant rate until after the 
peptide was introduced after 20 minutes and there was a sudden decrease in Δf from -26 
Hz to -31 Hz. After this sudden decrease, Δf increased to -25 Hz and remained constant 
during peptide incubation at until the final buffer rinse at 95 minutes. At the final buffer 
rinse Δf decreased at a steady rate to a final Δf value of -27 Hz. After the buffer was 
introduced, ΔD increased from ~0.1x106 to ~1.2x106 and then decreases to ~0.2x106. After 
peptide is introduced at 20 minutes, there is a drastic increase in dissipation from ~0.2x106 
to ~2.0x106. Then, ΔD decreases down to zero (0) and remains constant at zero (0) during 
peptide incubation. The value of ΔD increases from zero (0) to ~0.2x106 after the final 
buffer rinse.  
29 
 
Trace patterns for concentrations 0.01-0.25 µM showed 
similar trace graph trends 
 
When the bilayer was being formed the lipid vesicles first attached to the QCM-D 
sensor surface which added mass to the surface. The lipid vesicles then burst releasing the 
fluids within the vesicle forming a supported lipid bilayer (SLB). The frequency decreased 
when the vesicles were absorbed and then an increase in frequency was shown as soon as 
the vesicles ruptured to form the bilayer. The dissipation increased in response to the 
attachment of water-filled vesicles and after bilayer formation, dissipation decreased 
because the bilayer become more rigid than the vesicles. A complete bilayer could be 
characterized by a final Δf of ∼26 Hz and change in dissipation (ΔD) of ∼1x10-6 in the 
third harmonic. However, our data was more focused on what happened after the lipid 
bilayer formation.  
For concentrations 0.01-0.25 µM, when peptide was added and allowed to remain 
in contact with the bilayer, changes in frequency and dissipation were monitored 
continuously. The frequency responses at all overtones showed an initial decrease in 
frequency, and therefore an increase in mass, on the crystal as peptides attached to the 
bilayer. The dissipation responses at all overtones showed a decrease in dissipation 
suggests that the bilayer is becoming slightly more rigid.  
Figure 4 shows all of the overall changes of frequency and dissipation bar graphs 
for the lower concentrations of fCBD-LL37. These graphs are based on a frequency and 
dissipation scale of -3 to 3 Hz and 1E-6, respectfully. The changes of frequency and 
dissipation are very low for these concentrations. It is evident from the graphs that there 
is a greater difference of the changes of frequency and dissipation along the 3rd overtone, 
therefore the 3rd overtone has the longest bar.   
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Bar graphs including errors for concentrations 0.01-0.25 µM 
 
Figure 4: Bar graphs including error bars for fCBD-LL37 concentrations of 0.01-0.25 µM 
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For these concentrations, we performed a one-way ANOVA statistical analysis. 
This analyses showed that the variation in the overall Δf and ΔD were too insignificant. 
This insignificance means that there is not a lot of interaction occurring at the bilayer so 
there is no need for a further statistical analysis using the Tukey or SNK method.  
 
At 0.5 µM concentration fCBD-LL37 the graphs start showing 
a more noticeable decrease in Δf values  
 
 The concentration 0.5 µM fCBD, displayed reproducible interaction patterns 
throughout the various replicates. After bilayer formation, Δf remained constant around -
26 Hz until the peptide was introduced and there was a decrease from -26 Hz to -30 Hz. 
During peptide incubation Δf remained constant at -30 Hz until the final buffer rinse where 
there was a very small increase to -29 Hz. While Δf was decreasing, the ΔD values increase 
Figure 5: Frequency (Δf) and dissipation (ΔD) vs time line plot graphed in SgimaPlot. This graph shows a 
replicated experiment using a QCM-D of 0.5 concentration fCBD-LL37. In this graph range of dispersion in 
the dissipation lines can be observed from ~0 to ~0.5 x106 
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with dispersion in the overtones of Δf and ΔD. After the buffer was introduced, ΔD values 
increase from ~0.1x106 to ~0.5x106 and decreased from ~0.5x106 to zero (0) at about 20 
minutes. After the peptide was introduced, ΔD increased from zero (0) to about 0.4x106. 
During peptide incubation ΔD increased from ~zero (0) to ~0.1x106 and remained constant 
until the end of the experiment.  
An increase in dissipation indicates that the bilayer is becoming more rigid. 
However, the changes of frequency didn’t decrease which suggests that mass was not 
added onto the surface of the bilayer. This shows that there are minimal amounts of peptide 
attaching to the surface of the bilayer. 
 
 
 
 
 
 
 
 
 
 
 
 
 The figure above represents the bar graph for 0.5 µM concentration peptides. We 
are able to see that as frequency decreases, dissipation barely increases. From the trace 
responses, we were not able to fully tell if the frequency values were decreasing or 
increasing, but from the bar graphs, it is clear that the dissipation values increase slightly. 
Like stated earlier, this could indicate that there is only some attachment of peptide onto 
the surface of the bilayer.   
Figure 6: Bar graphs including error bars for fCBD-LL37 concentrations of 0.5 µM 
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At 1.0 µM concentration fCBD two (2) interaction patterns 
were observed with different dispersions throughout the 
overtones  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In Figure 7, after the bilayer is formed, there is decrease in Δf from -26 Hz to -
38Hz. The value of Δf remains relatively constant at -32 Hz until after the peptide is 
introduced where Δf shows a decrease from -26 Hz to -38 Hz. The Δf values in the 
overtones start to disperse more creating more distance between the overtones, ranging 
from -26 Hz to -38 Hz. After the peptide was introduced, ΔD increased from ~0.1x106 to 
~3.1x106. During the incubation period, the 3rd harmonic increased to around 1.8x106 
while the remaining harmonics remained at around 1x106. After the final buffer rinse, there 
Figure 7: Frequency (Δf) and dissipation (ΔD) vs time line plot graphed in SgimaPlot. This graph shows a 
replicated experiment using a QCM-D of 1.0uM concentration fCBD-LL37. In this graph range of dispersion in 
the dissipation lines can be observed from ~1.2x106 to ~3 x106 and frequency lines can be observed from ~-37 
Hz to ~-27 Hz. 
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is a slight decrease of frequency to around -36 Hz and an increase of dissipation of the 3rd 
harmonic to about 2.1x106 and the remaining harmonics to about 1.8x106.  
 
Starting from this concentration, we were able to notice more dispersion of the 
overtones in the trace responses. It was more evident that as dissipation increased, 
frequency decreased which indicates that mass is being adsorbed onto the surface of the 
bilayer. The separation of the 3rd overtone from the other overtones indicate that there is 
more activity along the surface of the bilayer only which indicates that the peptides are just 
attaching to the surface and not penetrating through the bilayer.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
Similar to the bar graphs for the 0.5 µM concentration of fCBD-LL37, the general 
trend of the changes of frequency and dissipation along the bilayer is the same. However, 
now the scale in which we measure our data is much higher at -50 to 50 Hz and 1E-6, 
respectively. This suggests that along the surface of the bilayer, there is more evidence of 
antimicrobial activity.  
 
 
 
Figure 8: Bar graphs including error bars for fCBD-LL37 concentrations of 1.0 µM 
35 
 
Higher concentrations of 5.0 µM and 10.0 µM concentration 
fCBD show the greatest range of dispersion in Δf and ΔD 
  
 
 
 
Experiments carried out using peptide concentrations 5.0 µM (Figure 9) and 10.0 
µM concentration showed reproducible graphs for all six (6) replicates of each 
concentration, see Appendix B. After bilayer is formed Δf remains constant at -26 Hz until 
the peptide is introduced at 25 minutes and Δf values decrease from -26 Hz to -50 Hz. 
During peptide incubation, Δf values slightly increase from -50 Hz to -40 Hz and there is 
dispersion throughout all the Δf overtones ranging from -40 Hz in the 3rd overtone to -50 
in the 11th overtone. After bilayer formation, the value of ΔD increased from zero (0) to 
~1.3x106 and when buffer was introduced ΔD decreased from ~1.3x106 to ~0.1x106. At 25 
minutes when peptide is flow through the QCM-D the frequency drastically decreased to 
approximately -50 Hz, while the dissipation increased to ~3.5x106. During incubation, the 
dissipation overtones started to disperse more having a greater distance between the 
Figure 9: Frequency (Δf) and dissipation (ΔD) vs time line plot graphed in SgimaPlot. This graph shows a replicated 
experiment using a QCM-D of 5.0uM concentration fCBD-LL37. In this graph range of dispersion in the dissipation lines can 
be observed from ~0.9x106 to ~1.8 x106 and frequency can be observed from ~-21 Hz and 1Hz. 
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different overtones, ranging from around 4.0x106 in overtone 11 to 6.0 x106 in overtone 3. 
 
At the concentration of 5.0 µM fCBD there is even greater dispersion throughout 
the frequency and dissipation trace responses than at concentration 1.0 µM fCBD. Using a 
peptide of 5.0 µM there is a greater decrease in frequency which indicates that there is an 
even greater adsorption of mass to the surface of the bilayer indicating that the bilayer is 
becoming more rigid by the addition of mass and increase in dissipation. Similarly, to 1.0 
µM the separation of the 3rd overtone from the other overtones indicate that there is more 
activity along the surface of the bilayer only which indicates that the peptides are just 
attaching to the surface and not penetrating through the bilayer.  
 
 
 
 
 
 
 
 
 
 
 
 
Similar to the 5.0µM fCBD, experiments carried out using 10.0 µM showed 
reproducible end values of Δf and ΔD. After bilayer is formed Δf remains constant at -26 
Hz until the peptide is introduced at 25 minutes and Δf values decrease from -26 Hz to -46 
Hz. During peptide incubation, Δf values decrease from -46 Hz to -60 Hz and there is 
dispersion throughout all the Δf overtones ranging from -36 Hz in the 3rd overtone to -46 
Figure 10: Frequency (Δf) and dissipation (ΔD) vs time line plot graphed in SgimaPlot. This graph shows a replicated 
experiment using a QCM-D of 5.0uM concentration fCBD-LL37. In this graph range of dispersion in the dissipation lines 
can be observed from ~0.9x106 to ~1.8 x106 and frequency can be observed from ~-21 Hz and 1Hz. 
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Hz in the 11th overtone. After bilayer formation, the value of ΔD increased from zero (0) 
to ~0.1x106 and when buffer was introduced ΔD decreased from ~0.1x106 to zero (0). At 
25 minutes when peptide is flow through the QCM-D the ΔD drastically increased to 
~6.0x106. During peptide introduction (Figure 10), frequency decreased and dissipation 
values increased from ~3.0x106 to ~6.0x106 until the lines overlapped during incubation. 
Dissipation values ranged from about ~6.0x106 to ~11.0x106 and frequency values ranged 
from about -44 Hz to -59 H.  
 
For this concentration, the frequency and dissipation changes cross one another 
completely. This suggests that the peptide is penetrating through the bilayer instead of just 
attaching to the surface. For this concentration, there is separation along all of the overtones 
which means that there is antimicrobial activity along the overtones, therefore validating 
that the peptide is penetrating through the bilayer.     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11:Bar graphs including error bars for fCBD-LL37 concentrations of 5.0 and 10.0 µM, as labeled 
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Similar to all other bar graphs described previously, as the overall changes of 
frequency increase, dissipation decreases. The 3rd overtone shows a greater difference in 
all cases indicating that there is increased activity along the 3rd overtone, which is the 
surface of the bilayer.  
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Chapter 5: Conclusions and Recommendations 
 
In order to develop a broad-spectrum chronic wound collagen dressing based on 
antimicrobial peptides (AMPs) or a bacteria resistant antibiotic based on AMPs, several 
obstacles have to be overcome. Due to the AMPs’ broad spectrum antimicrobial activity 
and anti-biofilm properties, they pose as an excellent alternative for current treatments for 
chronic wound infections and antibiotic resistant bacteria. The major reasons why AMPs 
have not been used for clinical applications is because the production cost is too high, 
costing $300-$500 per gram, and their mechanisms of action which is how they would 
interact in the body is still not understood well enough (Bray 2003; Vlieghe et al. 2010). 
These experiments carried out allowed us to observe how adding fCBD affected LL37 
bioactivity, provided a foundation for future research, and will eventually aid in the 
development of biopolymer-tethered AMPs for wound healing applications. 
 
In this study, the goal was to determine the action mechanism of one of these CBD 
peptides, fCBD-LL37 with a CBD derived from fibronectin, against zwitterionic 
phosphatidylcholine (PC) lipid bilayers. using a quartz crystal microbalance with 
dissipation (QCM-D). The QCM-D has a nondestructive flow making it able to collect data 
in realtime. We chose to study fCBD-LL37 because from prior research, it is found that 
fCBD is less cytotoxic than LL37 and cCBD-LL37 and preserves its antimicrobial activity 
(Lozeau et al, 2016). After carrying out experiments for eight (8) different concentrations 
with six (6) different replicates we observed some general trends in the data we collected 
(Appendix B). For all concentrations and replicates we took into consideration the time 
dependency of the experiment, peptide concentration and the lipid solution that was used. 
In general, it was shown that overall changes in dissipation (ΔD) and frequency (Δf) 
increase with higher concentrations of fCBD.This addition of mass can easily be seen in 
these higher concentrations due to the overtones being more spread out. For all 
concentrations of fCBD the outcomes of ΔD and Δf are relatively similar but they may 
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approach the mechanism via different pathways.  
 
General trends from the trace responses and Anova analyses show that for 
concentrations of f-CBD lower than 0.5um, the P value, which indicates the degree of 
significance of activity along the bilayer, is less than 0.05. Thus, deeming the data 
insignificant for further Tukey and SNK analysis. However, for concentrations of f-CBD 
from 0.5um-10.0um, produced P values lower than 0.05. For each of these higher 
concentrations, a Tukey and SNK analysis were completed. The results of these analyses 
showed that there is a great difference of depth between the 3rd and 5th overtones versus 
the 11th overtone, suggesting more activity along the surface of the bilayer. This indicates 
that the peptides are being attached to the surface of the bilayer but not completely 
penetrating the bilayer.  
 
The replicates of each concentration showed similar trace patterns within each 
concentration. For the concentrations 0.05 µM, 0.25 µM and 1.0 µM we observed two (2) 
different trace patterns which could suggest that there are two (2) different mechanisms of 
action present. From previous research, we know that LL37 usually displays either the non-
pore carpet model or the detergent-like carper model Porcelli et al., 2008). The research 
showed two (2) different trace patterns which could indicate that fCBD, like LL37, might 
display either the non-pore carpet model, the detergent-like carper model or both 
mechanisms. Due to the inconsistencies of the appearances of the peaks along the 
experiments, we also believe that it may not be a different mechanism, but rather some 
human error or software error. We recommend that further analysis be done by modeling 
the peptide-lipid interaction to monitor how the peptide is attaching the lipid surface in 
order to determine the exact mechanisms.  
 
This is an important and interesting research topic and we recommend that more 
people continue looking into fCBD-LL37 as a possible AMP for clinical use. For future 
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analysis more experimental replicates of each concentration need to be done keeping the 
variables more constant. The QCM-D is a highly sensitive piece of equipment that is affect 
by the slightest movements by user handling and different solutions being flown through. 
We also recommend consistency in the preparation of the peptide and lipid solutions 
because differences in those also affect the graphs. 
 
 The long term goal of this research is the determine an improved method of 
treatment for chronic wound infections and functional tissue repair. The research required 
to fully improve treatments is still yet insufficient and more analyses and modeling is 
needed to gain a better understanding of the specific mechanisms. A better understanding 
of the AMP structure function relationship in the tethered state is vital for the success of 
the efforts to develop a more efficient treatment method. We believe that determining how 
to use AMPs for clinical treatment will solve various health issues which would fix the 
problem with a permanent solution rather than putting a band aid on it and only fixing it 
temporarily. The achievement of this research will be beneficial for the improvement of 
patient health.     
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Appendix A: Examples of Antibiotics Currently 
Being Used and Their Functions 
 
Table 2: Examples of antibiotics currently being used and their functions 
Type of 
Antibiotic 
Function of Antibiotic Examples of Antibiotic 
Aminoglycoside 
Antibiotics 
Aminoglycoside antibiotics 
work by inhibiting bacterial 
protein synthesis. They are not 
well absorbed when given by 
mouth so are often given by 
injection, but may also be given 
as drops for some ear or eye 
infections. These antibiotics are 
only used when other 
antibiotics are not suitable or 
have not been effective, 
because they can sometimes 
cause problems with the 
kidneys or with hearing. 
 Amikin (amikacin) 
 Cidomycin injection 
(gentamicin) 
 Genticin injection 
(gentamicin) 
 Tobi nebuliser solution 
(tobramycin) 
 Tobramycin injection 
 Nivemycin (neomycin) 
Cephalosporin 
Antibiotics 
Cephalosporins are a group of 
broad-spectrum antibiotics that 
are commonly used to treat 
infections caused by a wide 
variety of bacteria, including 
more serious infections such as 
septicaemia, pneumonia, 
meningitis, biliary-tract 
infections, peritonitis, and 
urinary-tract infections. 
 Cefadroxil 
 Cefotaxime 
 Ceporex (cefalexin) 
 Distaclor (cefaclor) 
 Distaclor MR (cefaclor) 
 Fortum (ceftazidime) 
 Keflex (cefalexin) 
 Keftid (cefaclor) 
 Nicef (cefradine) 
 Orelox (cefpodoxime) 
 Rocephin (ceftriaxone) 
 Suprax (cefixime) 
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 Zinacef (cefuroxime) 
 Zinnat (cefuroxime) 
Macrolide 
Antibiotics 
Macrolide antibiotics have an 
antibacterial spectrum that is 
similar, but not identical, to that 
of penicillin, so are often used 
for people with a penicillin 
allergy or to treat penicillin-
resistant strains of bacteria. 
Macrolide antibiotics are 
particular useful for treating 
lung and chest infections. They 
are also used for skin infections 
and some sexually transmitted 
infections. 
 Clamelle (azithromycin) 
 Erythromycin 
 Ketek (telithromycin) 
 Klaricid (clarithromycin) 
 Klaricid XL 
(clarithromycin) 
 Tiloryth (erythromycin) 
 Zithromax (azithromycin) 
Penicillin 
Antibiotics 
Penicillin antibiotics are the 
most widely used groups of 
antibiotics. They are mainly 
broad-spectrum antibiotics that 
can be used for a wide variety 
of infections, such as 
respiratory tract infections, skin 
infections and urinary tract 
infections. Flucloxacillin is 
reserved for treating bacteria 
that are resistant to other 
penicillins.  
 Amoxicillin (eg Amoxil) 
 Co-amoxiclav (eg 
Augmentin) 
 Co-fluampicil 
 Crystapen 
(benzylpenicillin) 
 Flucloxacillin (eg 
Floxapen) 
 Magnapen (co-fluampicil) 
 Penbritin (ampicillin) 
 Penicillin V 
(phenoxymethylpenicillin) 
 Selexid (pivmecillinam) 
 Tazocin (piperacillin, 
tazobactam) 
 Timentin (ticarcillin) 
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Quinolone 
Antibiotics 
These are broad-spectrum 
antibiotics that can be used to 
treat a wide range of infections, 
particularly urinary tract and 
respiratory infections. 
 Avelox (moxifloxacin) 
 Ciproxin (ciprofloxacin) 
 Nalidixic acid 
 Tarivid (ofloxacin) 
 Tavanic (levofloxacin) 
 Utinor (norfloxacin) 
Sulphonamide 
Antibiotics 
The use of sulphonamides has 
decreased due to an increase in 
bacterial resistance and the 
development of other 
antibiotics that are more 
effective. 
 Septrin (co-trimoxazole) 
 Sulfadiazine 
Tetracycline 
Antibiotics 
Tetracycline antibiotics such as 
minocycline and 
oxytetracycline are commonly 
used to treat moderate to severe 
acne and rosacea, but can also 
be used to treat a wide range of 
other bacterial infections, 
including respiratory and 
genital infections. 
 Aknemin (minocycline) 
 Demeclocycline 
 Doxycycline (Vibramycin-
D, Vibrox) 
 Oxytetracycline 
 Tetracycline tablets 
 Lymecycline (eg 
Tetralysal) 
Other antibiotics There are several other 
antibiotics that don't fit into the 
groups above. These are used 
for more specific types of 
infections. 
 Azactam (aztreonam) 
 Chloramphenicol capsules 
 Clofazimine 
 Colomycin injection 
(colistin) 
 Cubicin (daptomycin) 
 Dalacin C capsules 
(clindamycin) 
 Dificlir (fidaxomicin) 
 Fasigyn (tinidazole) 
 Flagyl suppositories 
(metronidazole) 
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 Flagyl tablets 
(metronidazole) 
 Fucidin suspension 
(fusidic acid) 
 Fucidin tablets (sodium 
fusidate) 
 Hiprex (methenamine) 
 Kemicetine 
(chloramphenicol) 
 Meronem (meropenem) 
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Appendix B: Frequency vs Dissipation Graphs 
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0.25 µM concentration fCBD 
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5.0  µM concentration fCBD 
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5.0  µM concentration fCBD 
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10.0  µM concentration fCBD 
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10.0  µM concentration fCBD 
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